Skip to main content

Biomerica, Inc.

corporate_fare Company Profile

Biomerica, Inc.

BMRA·NASDAQ·Life Sciences·CIK 0000073290

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica, Inc. (NASDAQ:BMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for BMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-16, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BMRA spans 10-Q, 10-K/A, 10-K, 8-K.

Recent high-impact activity:

  • Biomerica Posts $1.20 Per-Share Q1 Loss as Cash Crunch Deepens
  • Biomerica Q1 Loss Widens to $1.2M; Going-Concern Doubt Reiterated Despite $2.7M Cash
  • Biomerica 10-K/A Reveals CEO's $500K Related-Party Note and New Finance Chief
  • Biomerica 10-K: Going Concern Warning, 300M Authorized Shares, Nasdaq Delisting Risk
  • Biomerica Secures $2.23M via Private Placement at $1.60/Share, Grants B. Riley Board Seat

Financial Snapshot

Fiscal year ended May 31, 2026
Revenue
$4.45M
Net Income
-$3.77M
Diluted EPS
-$1.30
Op. Cash Flow
-$3.42M
Gross Profit
$362K
Operating Income
-$5.32M
Cash & Equivalents
$1.31M
Debt / Equity
0.00×
Net Margin
-84.8%
Shares Outstanding
3.2M sh
Source: 10-K · filed 2026-08-31 · accession 0001493152-26-040851

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 10,485 shares in BMRA as of the October 15, 2026 settlement, a 62.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 26, 2026, 48.0% of BMRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,485 shares as of October 15, 2026
Change vs prior period▼ 62.1%
Days to cover1.00 at avg daily volume of 14,229
Daily short volume (FINRA facilities)48.0% of 8,594 shares on October 26, 2026
5-day average short volume48.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BMRA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-25.

2 shelf registrations

$250M Universal Shelf Registered · No Immediate Dilution

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$1.72
52-week range · as of 2026-10-15 $1.45 – $3.21
Market cap
$7.91M
Volume
10.4K (0.5× avg)
3-mo avg 20K
Live data · 2026-10-27 11:44 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed BMRA - Latest Insights

BMRA
Oct 16, 2026, 8:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.72 info
Change: -$0.030 (-2%) info
Market Cap: $7.91M info
BMRA
Oct 15, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $1.72 info
Change: -$0.155 (-8%) info
Market Cap: $7.91M info
BMRA
Sep 28, 2026, 5:00 PM EDT
Filing Type: 10-K/A
Importance Score:
7
Price at Filing: $2.39
Real-time Price: $1.72 info
Change: -$0.6699 (-28%) info
Market Cap: $7.91M info
BMRA
Aug 31, 2026, 5:00 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.09
Real-time Price: $1.72 info
Change: -$0.370 (-18%) info
Market Cap: $7.91M info
BMRA
Aug 26, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.72 info
Change: +$0.030 (+2%) info
Market Cap: $7.91M info
BMRA
Jun 04, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.72 info
Change: -$0.425 (-20%) info
Market Cap: $7.91M info
BMRA
May 28, 2026, 8:19 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.65
Real-time Price: $1.72 info
Change: -$0.930 (-35%) info
Market Cap: $7.91M info
BMRA
Apr 13, 2026, 6:57 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $1.72 info
Change: -$0.360 (-17%) info
Market Cap: $7.91M info
BMRA
Apr 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.08
Real-time Price: $1.72 info
Change: -$0.360 (-17%) info
Market Cap: $7.91M info
BMRA
Mar 18, 2026, 8:19 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.26
Real-time Price: $1.72 info
Change: -$0.540 (-24%) info
Market Cap: $7.91M info
BMRA
Mar 05, 2026, 8:20 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $1.72 info
Change: -$0.360 (-17%) info
Market Cap: $7.91M info
BMRA
Jan 14, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.70
Real-time Price: $1.72 info
Change: -$0.975 (-36%) info
Market Cap: $7.91M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets